Sponsored by: APS and ASPET Co-sponsors: Burroughs Wellcome Fund

Slides:



Advertisements
Similar presentations
Global Forum on Bioethics in Research – nearing 10 years of dialogue
Advertisements

Biomanufacturing Sciences Concentration in CBE Dr. Henry Lamb Associate Professor Department of Chemical & Biomolecular Engineering Biomanufacturing Training.
MEETING OF THE FEDERAL PARTNERS IN TECHNOLOGY TRANSFER (FPTT) – NATIONAL JUNE 1 ST 2005 EILEEN RAYMOND – INDUSTRIAL AFFAIRS.
Integrative Organs Systems Scientists and Drug Discovery: The Link Between Big Pharma and Academia Glenn A. Reinhart, Ph.D. Senior Group Leader Integrative.
Open Access – a funder’s perspective Robert Terry Senior Policy Adviser The Wellcome Trust.
Overview Division of Viral Products Office of Vaccines Research and Review Laboratory of Methods Development Site Visit January 9, 2003.
Office of Biotechnology Products
An Overview of the Canadian Pharmaceutical Industry
Biotechnology Unit 3.04.
BIOINFORMATICS CSMN 601 Zhongchun Wang. AGENDA What is Bioinformatics History Genome ABC Technology Industry Overview Ethical, Legal, and Social Implications.
Genomics Commercialization Glen Schuler Managing Director, Industry Liaison Office University of Saskatchewan.
CBER Regulatory Laboratory Planning & Preparedness for SARS-related Biologics Products Kathryn M. Carbone MD Associate Director for Research, Acting, Center.
External Reports Overview Presentation for the ENG Advisory Committee By Michael Reischman Deputy Assistant Director for Engineering.
Center for Biologics Evaluation and Research Applying Regulatory Science to Advance Development of Innovative, Safe and Effective Biologic Products Carolyn.
Working Collaboratively Toward Effective Decision-making Frances D. Butterfoss, PhD, MSEd Center for Pediatric Research James M. Krieger, MD, MPH University.
Center for Biologics Evaluation and Research FDA Overview Site Visit Carolyn A. Wilson, Ph.D. Associate Director for Research.
Conflict of Interest in Medical Research, Education, and Practice Presentation for Secretary’s Advisory Committee on Human Research Protections July 22,
National Institute on Aging Richard J. Hodes, M.D. Director,NIA/NIH/DHHS ADC Meeting – NIH Roadmap and Budget October 2003.
1 Course. 3 U nique options. Biomedical Science Discoveries, Diagnostics and Cures 1.
Bioinformatics Curriculum Guidelines: Toward a Definition of Core Competencies Lonnie Welch School of Electrical Engineering & Computer Science Biomedical.
School of Medicine Shared Resource Facilities The School of Medicine provides direct support and oversight to 21 SOM shared resource facilities. Their.
1 Life Technologies™ Proprietary | AIPLA Winter Meeting Presentation January 2013.
NIGMS Training in Systems & Integrative Science Peter C. Preusch, Ph.D. Program Director Pharmacological Sciences Training Grant Program, NIGMS, NIH LSRO.
Ministry of Research and Innovation Research Programs International Society for Computational Biology July 23, 2008.
Bio-Tech Israel 2005 Conference & Exhibition May 24 – 26, 2005 David Intercontinental Hotel, Tel Aviv, Israel.
What is Biotechnology?.
The Federal German Funding Initiative Systems for Life - Systems Biology Structure – Coordination Jens Doutheil DECHEMA e.V. Frankfurt.
The Innovative Medicines Initiative (IMI) High level the IMI Concept, Strategic Research Agenda and Call topics Eva Lindgren.
The Human Genome Project: prospects for cardiology Claude L’Enfant MD Director, National Heart, Lung, and Blood Institute National Institutes of Health,
Managing Medical R&D Defining and Realizing Clinical and Commercial Value David J. Wierz Senior Director Commercial Investment & Pricing Strategy Wyeth-Ayerst.
This curriculum is available on the NWABR website, Permission granted for educational use ©2012 Northwest Association for Biomedical.
A New Oklahoma Bioinformatics Company. Microarray and Bioinformatics.
The Status and Future of Integrative and Organ Systems Sciences October 20 – 21, 2002 Bethesda, MD Sponsored by:APS and ASPET Co-sponsors: Burroughs Wellcome.
MEDICAL INNOVATION March What Are The Public Health Benefits of Medical Innovation? Breakthrough medicines New devices Innovative medical procedures.
“Career Opportunities: Supply and Demand Factors Edward J. Zambraski, Ph.D. Department of Cell Biology & Neuroscience Rutgers University.
D.Zucker Draft-EB09 Ethics & Academic Technology Transfer: Patients, Products and Public Trust Deborah Zucker, MD, PhD, Tufts Medical Center.
Structural Genomics Consortium releases 1,000th protein structure The Structural Genomics Consortium (SGC), an international public-private partnership.
Location, mission, & overview of the curriculum …… J. Peter Gergen (Director, Undergraduate Biology) UNDERGRADUATE BIOLOGY at STONY BROOK UNIVERSITY.
The FDA: Basic Facts It takes 12 to 15 years to develop a single drug Only 1 in 10,000 potential medications makes it completely through the process Only.
Consortium for Interdisciplinary Studies on Science for Aging.
New Technologies: the Role of the Private Sector Biotech’s Perspectives on Vaccine Development Alliances Peter Young CEO, AlphaVax, Inc.
FDA Office of Orphan Products Development
Life Sciences Research Office, Inc. (LSRO) Michael Falk Executive Director.
Research in the Office of Vaccines Research and Review: Vision and Overview Jesse Goodman, M.D., M.P.H. Director, Center for Biologics Evaluation and Research.
What did you observe?. What is the main difference between Subject A and Subject B?
The Regulatory Science of Regenerative Medicine Celia M. Witten, Ph.D., M.D., Director Office of Cellular, Tissue and Gene Therapies Center for Biologics.
Research in the Office of Cellular, Tissue and Gene Therapies: Vision and Overview Jesse Goodman, M.D., M.P.H. Director, Center for Biologics Evaluation.
Center for Biologics Evaluation and Research, FDA Site Visit Introduction Kathryn M. Carbone, M.D. Associate Director for Research.
Bachelor of Biomedical Science Department of Biological.
1 Modelling and Simulation EMBL – Beyond Molecular Biology Physics Computational Biology Chemistry Medicine.
RAS Initiative at the Federally Funded Research and Development Center at Frederick Presented By: Sara S. Hook October 1, 2015.
Figure 14-1 Molecular Biology of the Cell (© Garland Science 2008)
Division of Cancer Treatment and Diagnosis Presented By: Michael Difilippantonio, Ph.D. October 1, 2015.
The role of basic research in antibiotic discovery and development Prof Jeff Errington FMedSci FRS Centre for Bacterial Cell Biology, Newcastle University.
The National Science Foundation Independent Federal Agency Support for all fields of fundamental science and engineering.
Lecture 5 INTRODUCTION TO ANIMAL BREEDING Who Is A Geneticist? A scientist who studies genetics, the science of heredity and variation of organisms and.
VxP Biologics The Biologics Service Company
Lithuania: Biotechnology
Parallel Integration between BioVentures
Classification of proteins in PC-3 cell-released microvesicles by GOslim annotations. Classification of proteins in PC-3 cell-released microvesicles by.
مهارات التدريس الفعال.
Biomolecular Networks Initiative
FDA Tox Working Group Which goals of the FDA Roadmap are most important to FDA stakeholders? Integration of predictive technologies Replacing animal tests.
Distribution of the phosphoproteins based on GO analysis, including biological process (Left) and cellular component (Right). Distribution of the phosphoproteins.
Integration of Genomic Medicine into Pathology Residency Training
Image analysis and HER-2/neu slide scoring.
Eight serum analytes with greatest differences in levels between clinically infected and non-infected neonates. Eight serum analytes with greatest differences.
Common Implementation Strategy for the Water Framework Directive (2000/60/EC) Work Programme : Strengthening EU Water Policy through the 2nd River.
Bio-Rad Overview and Statement of Interests
Figure 5-1 Molecular Biology of the Cell (© Garland Science 2008)
Presentation transcript:

The Status and Future of Integrative and Organ Systems Sciences October 20 – 21, 2002 Bethesda, MD Sponsored by: APS and ASPET Co-sponsors: Burroughs Wellcome Fund Merck Research Laboratories

Definitions Reductionist approaches are aimed at identifying molecular and cellular events, studied in purified form or in isolated systems and including genomics, proteomics, biochemistry and cell biology Integrative and Organ Systems approaches are aimed at understanding how intact biological systems function at the level of whole animals, organs and organ systems (but not in the clinic).

Life Sciences Research Office (LSRO) Michael Falk Executive Director

Mission To benefit society by evaluating biological information and scientific opinion for the public and private sectors

Steering Committee James R. Bloedel Joseph R. Haywood D. Euan MacIntyre Peter C. Preusch James H. Woods Edward J. Zambraski

HGS Annual Reports Founded in 1992 – leader in the discovery of human and microbial genes 1995 “success in turning our leadership in gene discovery into leadership in the creation of proprietary pharmaceutical products” 1997 “year of change for our company, as we began to implement clinical development of our own drugs” 1998 “significant progress in its ongoing transition to a fully integrated biopharmaceutical company that discovers, develops, manufactures and markets” 2000 “genomics” found only once